CX Institutional Has $7.71 Million Stake in Johnson & Johnson $JNJ

Key Points

• CX Institutional reduced its Johnson & Johnson stake by 13.5% in the second quarter, selling 4,720 shares and retaining 30,364 shares valued at approximately $7.71 million. Institutional investors and hedge funds collectively own 69.55% of JNJ.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $267.48. JNJ recently beat quarterly EPS and revenue estimates, while full-year 2026 EPS guidance is $11.60–$11.75.
• Johnson & Johnson is pursuing growth through its FDA-authorized OTTAVA robotic surgery system and strong oncology performance, while continuing to offer a quarterly dividend of $1.34, equivalent to a 2.1% yield at the reported share price.

CX Institutional trimmed its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 13.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 30,364 shares of the company's stock after selling 4,720 shares during the quarter. CX Institutional's holdings in Johnson & Johnson were worth $7,711,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in JNJ. Auto Owners Insurance Co lifted its position in Johnson & Johnson by 22,225.6% in the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company's stock worth $1,436,633,000 after buying an additional 69,108,368 shares in the last quarter. Norges Bank purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at $6,924,523,000. Capital World Investors acquired a new position in shares of Johnson & Johnson in the fourth quarter worth $2,005,942,000. Diamant Asset Management Inc. raised its holdings in shares of Johnson & Johnson by 24,436.5% during the first quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company's stock worth $109,338,000 after acquiring an additional 4,454,778 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Johnson & Johnson by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company's stock worth $49,740,362,000 after acquiring an additional 3,731,074 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of recent research reports. Morgan Stanley boosted their target price on Johnson & Johnson from $284.00 to $294.00 and gave the company an "overweight" rating in a research note on Thursday, July 16th. Wall Street Zen downgraded Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Saturday. Scotiabank reaffirmed an "outperform" rating and set a $305.00 price objective on shares of Johnson & Johnson in a research report on Thursday, July 16th. Barclays boosted their target price on shares of Johnson & Johnson from $234.00 to $255.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 15th. Finally, Bank of America raised their price target on shares of Johnson & Johnson from $254.00 to $263.00 and gave the company a "neutral" rating in a report on Friday, July 10th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $267.48.

Insider Transactions at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the sale, the executive vice president owned 23,003 shares of the company's stock, valued at approximately $5,779,963.81. The trade was a 50.06% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.16% of the company's stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson received FDA authorization for OTTAVA, its robotic-assisted surgical system, and is preparing for market introduction. Management discussed the system’s design, potential operating-room benefits and commercialization plans, creating a potential new growth platform beyond JNJ’s established pharmaceutical and medical-device businesses. Johnson & Johnson Discusses FDA Authorization and Market Introduction of OTTAVA Robotic Surgical System
• Positive Sentiment: Commentary from Jim Cramer characterized OTTAVA’s FDA milestone as a catalyst that improved sentiment toward JNJ after investors initially underappreciated the company’s strong earnings report. The assessment is opinion-based, but it reflects increased visibility for the robotics opportunity. Jim Cramer Analyzes Johnson & Johnson After Surgical Robotics Milestone
• Positive Sentiment: Johnson & Johnson’s oncology business delivered strong second-quarter growth, supported by Darzalex, Erleada and newer cancer treatments. Continued oncology momentum could help offset mature-product pressure and support long-term earnings growth. J&J's Strong Q2 Oncology Performance Fuels Future Growth Hopes
• Positive Sentiment: Wells Fargo raised its JNJ price target from $272 to $282 and maintained an “overweight” rating, signaling confidence in the company’s earnings outlook and growth initiatives. Wells Fargo Price Target Update
• Positive Sentiment: Reports also highlighted a roughly $3.5 billion biotech transaction or strategic move that expands JNJ’s oncology pipeline, potentially strengthening its future pharmaceutical portfolio. Johnson & Johnson Oncology Pipeline Expansion
• Neutral Sentiment: Market coverage continues to present JNJ as a defensive, dividend-oriented value stock, particularly as technology shares weaken and healthcare attracts broader value-ETF inflows. This may support demand but is not a company-specific catalyst. The S&P 493 Are Staging a Comeback
• Negative Sentiment: OTTAVA must compete with robotic-surgery systems that entered the market earlier, so FDA authorization does not guarantee rapid adoption or meaningful near-term revenue. Investors may also view JNJ’s valuation as demanding after its strong run.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $254.54 on Tuesday. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The firm has a fifty day simple moving average of $246.25 and a 200-day simple moving average of $238.80. The stock has a market capitalization of $613.41 billion, a price-to-earnings ratio of 29.49, a PEG ratio of 2.43 and a beta of 0.24. Johnson & Johnson has a 1-year low of $166.64 and a 1-year high of $274.90.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. Johnson & Johnson's revenue was up 6.6% compared to the same quarter last year. During the same period last year, the business posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, sell-side analysts expect that Johnson & Johnson will post 11.69 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be given a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson's dividend payout ratio (DPR) is currently 62.11%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.